Deerfield Management Company is a New York City-based investment firm founded with a mission to advance healthcare and improve global health outcomes. With a robust in-house ecosystem and a multidisciplinary team, Deerfield operates at the intersection of venture capital, scientific research, and strategic innovation. The firm collaborates with academic institutions, startups, and corporations to fund, incubate, and scale solutions that drive meaningful transformation across the healthcare landscape. Its approach blends scientific rigour, operational support, and capital access to help breakthrough therapeutics and technologies reach patients faster.
Deerfield invests across the healthcare continuum, with an emphasis on therapeutics, digital health, care delivery models, and AI-driven technologies.
The firm supports early-stage through growth-stage ventures that can reshape medical paradigms, improve care access and efficiency, and enhance health system performance. Particular attention is given to companies leveraging machine learning, drug development innovation, and platform technologies with high potential for impact.
In May 2025, Deerfield Management announced the close of its third dedicated healthcare venture fund, the Deerfield Healthcare Innovations Fund III, with over $600 million in committed capital. The fund is designed to fuel innovation in therapeutics, medical technology, healthcare delivery, and AI-powered solutions.
It continues Deerfield’s strategy of combining scientific and operational excellence with patient-centric investment. Fund III is bolstered by Deerfield’s deep network, including partnerships with 29 leading research institutions and nine industry collaborators.
A unique aspect of the fund is its philanthropic component - allocating a portion of profits not distributed to limited partners to the Deerfield Foundation, which focuses on improving child health globally.
This fund extends Deerfield’s commitment to driving innovation while fostering long-term, systemic improvements in global healthcare delivery.
Leadership
Deerfield is led by James Flynn, Managing Partner, who has overseen the firm’s transformation into one of the leading healthcare-focused investment platforms. The firm’s leadership includes seasoned professionals with backgrounds in clinical medicine, biostatistics, data science, drug development, and venture capital.
Investment Strategy
The firm deploys capital through a combination of direct investments, collaborative research agreements, and internally incubated ventures. Its in-house teams - such as Deerfield Discovery and Development (3DC) and Deerfield Intelligence - bring together scientists, engineers, and business leaders to rigorously evaluate and operationalize novel healthcare innovations.
Deerfield also operates Cure, a healthcare innovation campus in New York City that provides lab facilities, community space, and infrastructure for growing healthtech companies. This hands-on, ecosystem-driven approach distinguishes Deerfield as a long-term partner for companies pursuing breakthrough solutions in healthcare.
Notable Investments
Deerfield’s portfolio spans hundreds of healthcare innovations and ventures, including investments in high-impact therapeutic companies, AI-powered diagnostics, and health delivery platforms.
Many of these startups were launched or scaled in partnership with Deerfield's internal teams or through its university-backed initiatives. While specific names from Fund III are not yet disclosed, the firm has a long history of backing companies that go on to achieve FDA approvals, commercial success, and global impact.
Investment and Partnership inquiries to Karen Heidelberger: Karenh1@deerfield.com
Deerfield Foundation inquiries to Mark Veich: Mveich@deerfieldfoundation.org
CURE. inquiries: info@wewillcure.com
